SNDX - Syndax Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
10.09
0.00 (0.00%)
As of 11:03AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close10.09
Open10.66
Bid10.01 x 800
Ask10.07 x 900
Day's Range9.92 - 10.16
52 Week Range3.39 - 11.11
Volume33,892
Avg. Volume145,762
Market Cap273.81M
Beta (3Y Monthly)2.23
PE Ratio (TTM)N/A
EPS (TTM)-2.36
Earnings DateNov 4, 2019 - Nov 8, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.71
Trade prices are not sourced from all markets
  • 3 Hot Healthcare Stocks That Won’t Break the Bank
    TipRanks

    3 Hot Healthcare Stocks That Won’t Break the Bank

    Given the uncertain economic climate, investors are looking for sectors of the market that will provide refuge. Many analysts are pointing to the healthcare space. While the healthcare segment of the S&P 500 is down 2% over the last month, analysts believe that this sector contains compelling investment opportunities. Investors looking to break into the space don’t have to spend a lot of money to do so. With the help of analysts, we found 3 bargain healthcare stocks under $10 that appear poised for long-term growth.   CymaBay Therapeutics Inc. (CBAY)CymaBay develops and commercializes therapies used to treat patients with liver and other chronic diseases. Its most advanced clinical candidate is the seladelpar drug that could be used to treat primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH), or autoimmune liver diseases. The biopharma stock is currently trading at $5.83, with analysts saying share prices have the potential to keep going up. Coming on the heels of its second quarter earnings release, the company looks strong. CBAY has made a significant investment in the development of new and existing treatments. According to the August 7 release, research and development spending increased from $14.4 million in the year-ago quarter to $21.1 million.      Management pointed out that the investment in research and development already appears to be paying off. Data from CBAY’s paired liver biopsy study of seladelpar for NASH shows a favorable safety and tolerability profile at all doses. Not to mention the FDA accepted an Investigational New Drug (IND) application to begin a Phase 2 clinical study for seladelpar use in treating primary sclerosing cholangitis (PSC), a chronic cholestatic liver disease that causes diffuse inflammation and fibrosis of the bile ducts. Currently, there aren’t any FDA-approved treatments for PSC on the market. President and CEO Sujal Shah said, “In the second quarter of 2019, we made significant progress advancing the development of seladelpar for PBC and NASH and began activities to further diversify development into PSC. Enrollment in our ENHANCE Phase 3 registration study in PBC, expected to be completed by year-end, continued on track during the quarter. Topline 12-week results from our 52-week, dose-ranging Phase 2b study in NASH showed clinically meaningful reductions in multiple biomarkers of inflammation and liver injury despite minimal reductions in total liver fat.” Ed Arce, a four-star analyst according to TipRanks, agrees that the investment will bolster CBAY’s long-term growth narrative. On August 8, he reiterated his Buy rating and $12 price target. The H.C. Wainwright analyst believes share prices could soar by 106% over the next twelve months. The rest of the Street is bullish on this healthcare stock. CBAY has a ‘Strong Buy’ analyst consensus and a $14 average price target, suggesting 137% upside potential. Karyopharm Therapeutics Inc. (KPTI)Karyopharm Therapeutics is a clinical stage pharmaceutical company that develops treatments for cancer and other diseases. Its drugs directly target nuclear transport and related targets. KPTI is trading at $8.86, with some analysts saying more upside is set to follow. On July 3, KPTI’s XPOVIO received accelerated approval from the FDA. The drug was approved for the combined use with dexamethasone to treat adult patients who have relapsed or refractory multiple myeloma and have already received at least four therapies. After the approval, XPOVIO became commercially available in the U.S. on July 9. Management stated, “Early prescribing trends are encouraging with robust demand from both academic and community-based physicians throughout the U.S. with early prescriptions being filled for patients with Medicare and commercial insurance coverage.”  KPTI has also made substantial efforts to expand its reach. It submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for conditional approval of XPOVIO’s combined use with dexamethasone. Not to mention its Pivotal Phase 3 BOSTON study is in progress testing XPOVIO’s combined use with proteasome inhibitor Velcade (bortezomib) and low dose dexamethasone (SVd). The treatment would be used for patients with multiple myeloma that have only received one to three therapies.Edward White, a five-star analyst, believes XPOVIO’s success will fuel KPTI’s continued growth. “We base our $32 price target on probability-adjusted revenue forecasts for XPOVIO (selinexor). We use a net present value of $7.91 for our revenue forecast through 2026, that includes the approval of Xpovio in penta-refractory multiple myeloma, a 40% probability of success (POS) for XPOVIO in combination treatment for multiple myeloma, a 30% POS for 25% POS for XPOVIO in solid tumors,” he said. On August 6, the H.C. Wainwright analyst reiterated his Buy rating and $32 price target, implying 261% upside. One-star analyst, Eric Joseph said, “Our doctor survey supports a strong XPOVIO launch and long-term outlook.” On July 23, the J.P. Morgan analyst upgraded KPTI to a Buy and raised the price target from $8 to $16. He believes share prices could rise 81% over the next twelve months. KPTI has a ‘Strong Buy’ analyst consensus and a $20 average price target, suggesting 128% upside potential. Syndax Pharmaceuticals, Inc. (SNDX)The last healthcare stock on our list also develops treatments for cancer patients. With Syndax currently trading at $9.89, many analysts are saying now’s the time to get on board.On August 7, the company reported a second quarter net loss of $15 million or $0.47 per share. However, its loss narrowed from $18.4 million or $0.74 per share in the year-ago quarter. SNDX was also able to cut general and administrative costs from $4.5 million in the prior-year quarter to $3.5 million. The company’s most promising candidate is its entinostat treatment for breast cancer. In May 2019, E2112 trial passed its fourth interim overall survival (OS) analysis. The endocrine-based therapy could be a catalyst for SNDX, with results from the study expected to be released in the fourth quarter of 2019. Investors got another reason to be excited in July when the FDA approved the company’s IND application to start a Phase 1/2 trial for SNDX-5613, a highly selective Menin inhibitor to treat relapsed or refractory acute leukemias. SNDX is also researching drugs to treat chronic graft versus host disease (cGVHD). White, who also covers SNDX, believes that the company’s entinostat drug has the potential to fuel continued growth. On August 8, the analyst reiterated his Buy rating and $16 price target, suggesting 62% upside potential. “We base our $16 price target on probability-adjusted revenue forecasts for entinostat in combination treatment for advanced HR+, HER2- breast cancer. We use the net present value of our revenue forecast through 2027, apply a 40% POS for HR+, HER2- breast cancer, with a 3x price/sales multiple,” he said. Four-star analyst, Harshita Polishetty, agrees that its breast cancer drug is especially promising. “Taken as a whole, we believe the next preplanned overall surival (OS) interim analysis for E2112, scheduled for 4Q19, is a very important catalyst for the company. Overall, we remain focused on the potential of entinostat in HR+, HER2- breast cancer,” the B.Riley FBR analyst said. On August 8, he reiterated his Buy rating and $26 price target, implying 163% upside potential. Polishetty has a 62% success rate and gets an average return of 27% per rating. SNDX has a ‘Strong Buy’ analyst consensus and an average price target of $19, indicating 95% upside. Discover the Analysts’ Top-Rated Stocks right now

  • Thomson Reuters StreetEvents

    Edited Transcript of SNDX earnings conference call or presentation 7-Aug-19 8:30pm GMT

    Q2 2019 Syndax Pharmaceuticals Inc Earnings Call

  • Looking At Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) From All Angles
    Simply Wall St.

    Looking At Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) From All Angles

    Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is a company with exceptional fundamental characteristics. Upon building up...

  • Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Lags Revenue Estimates
    Zacks

    Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Lags Revenue Estimates

    Syndax (SNDX) delivered earnings and revenue surprises of -6.82% and -2.82%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • PR Newswire

    Syndax Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Clinical and Business Update

    - IND cleared for SNDX-5613, highly selective menin inhibitor for treatment of MLL-rearranged and NPM1-mutant acute leukemias - - Final interim OS analysis for E2112 expected in 4Q19 - - Company to host ...

  • PR Newswire

    Syndax to Participate in the BTIG Biotechnology Conference

    WALTHAM, Mass. , Aug. 5, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing ...

  • PR Newswire

    Syndax to Announce Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 7, 2019

    WALTHAM, Mass. , July 31, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing ...

  • Will Syndax Pharmaceuticals (SNDX) Report Negative Q2 Earnings? What You Should Know
    Zacks

    Will Syndax Pharmaceuticals (SNDX) Report Negative Q2 Earnings? What You Should Know

    Syndax (SNDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • 7 Stocks to Buy With Over 20% Upside From Current Levels
    InvestorPlace

    7 Stocks to Buy With Over 20% Upside From Current Levels

    Will the rally ever end?! Stocks continue to climb to record levels. Boosted by strong earnings and the promise of U.S.-China trade talks, the S&P 500 is now up over 20% year to date. That means upside potential can look limited from these lofty heights and finding stocks to buy seems a daunting task.Source: Shutterstock But there are still some select stocks out there primed to move higher. If you're looking for a quick boost to your portfolio, look no further. These are 7 stellar stock picks -- and I will explain why.First of all each of these stocks has over 20% upside potential. This is from the current share price to the average analyst price target. (And some of these stocks have far more than 20% upside potential.) Secondly, all these are "Buy" rated-stocks according to Street consensus -- or all the stock's ratings for the last three months. And last but not least, when you see the analyst investor reports on these stocks, it's clear that these are very promising companies with serious growth to come.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Semiconductor Stocks to Buy for Your Inner Geek I found these stocks using TipRanks' stock screener. This nifty screener enables you to search for stocks with a bullish rating from the Street's best analysts. Plus you can screen for only stocks with 20% upside potential and above. So see what you think of the following 7 stocks to buy now: Stocks to Buy: Stitch Fix (SFIX)Stitch Fix (NASDAQ:SFIX) shares enjoyed an incredible run at the start of the year. Shares are currently trading up 54% year-to-date. However it's not all smooth sailing -- the online personal shopping service has lost 14% in the last month. That's due to decelerating active client growth from 31% YoY as of July 2017 to 17% YoY as of April 2019.Luckily analysts are not concerned. In fact, it's quite the opposite. The stock has just received two back-to-back upgrades from the Street."Shares are now ~23% below our target price and trading at 1.3x CY:20 sales (below the historical average). Given our increasing confidence in the management team's ability to drive continued ARPU growth and healthy net client growth, we believe the recent weakness offers an attractive entry point" cheers five-star Stifel Nicolaus analyst Scott Devitt.He has just upgraded FIX from "hold" to "buy," with a price target of $35 (27% upside potential). Similarly Goldman Sachs' Heath Terry also upgraded FIX, with a $38 price target (38% upside potential). According to Terry, FIX shows "compelling upside potential" thanks to its expansion into plus-size, kids', and men's clothing. Terry is also optimistic about the company's recent move into the UK.Terry -- who also has a five-star track record -- tells investors: "We believe product innovation, operational efficiencies, and geographic expansion, combined with the increase in retail store closures (particularly in apparel) represent significant opportunities for further outperformance." Interested in Stitch Fix stock? Get a free SFIX Stock Research Report. Syndax Pharmaceuticals (SNDX)Source: Shutterstock Syndax Pharmaceuticals (NASDAQ:SNDX) has a strong purpose. The company wants to create a future where people with cancer live longer and better than ever before. And it is certainly making progress in realizing this goal. The company has just announced that the IND (investigational new drug application) for its targeted Menin inhibitor, SNDX-5613, has been cleared by the FDA.Syndax will now run will run a Phase 1/2 open-label trial in patients with r/r leukemia. Top-rated Nomura analyst Christopher Marai argues that the drug has the potential to be a blockbuster i.e. an extremely popular drug delivering annual sales of over $1 billion.He has just reiterated his SNDX buy rating with a $16 price target (78% upside potential). The analyst is confident that data is possible by the end of this year, writing: "We believe that the menin inhibition approach has potential for rapid POC (proof of concept) data, possibly by ASH (YE19)." * 7 Oversold Stocks To Buy Right Now He concludes "The program could become a blockbuster opportunity." Note that shares have already doubled year-to-date. But according to the Street significant further growth lies ahead. The average analyst price target of $19 indicates upside potential of 115%. Get the SNDX Stock Research Report. Morgan Stanley (MS)Source: Shutterstock Morgan Stanley (NYSE:MS) has only buy ratings from the Street right now. The company just reported stellar earnings for the second quarter against a choppy operating backdrop. Meanwhile the average analyst price target of $60 suggests shares can surge over 30% in the coming months.Revenue of $10.24 billion exceeded consensus estimate by around $250 million. Likewise EPS of $1.23 crushed the expected $1.14 consensus estimate. The beat came from strong results in both the firm's wealth management and investment management divisions.Morgan Stanley's CFO Jonathan Pruzan revealed that rising markets helped in "both the wealth business, in terms of the assets we manage, as well as our investment management business."I am also encouraged by a recent upgrade from Citigroup analyst Keith Horowitz. He boosted his price target from $48 to $52, citing an opportunity to increase exposure to a high quality franchise with limited rates exposure."We see Morgan Stanley net income growth of 2-3% over the next two years by continuing to gain market share in both its institutional and retail franchises, which compares more favorably against the flat to slightly declining net income growth among the rest of the bank universe" the analyst told investors. Shares are currently up 15% year-to-date. Get the MS Stock Research Report. The RealReal (REAL)Source: Shutterstock Welcome to a brand-new investing opportunity. This is a stock I am keeping a close eye on right now. Luxury resale website The RealReal (NASDAQ:REAL) has just made a dazzling market debut with a $300 million IPO. Despite pricing shares above the expected $17-$19 range at $20, the stock opened for trading at $28.90, up 44.5%."We see a strong opportunity for The RealReal to be a dominant player in the luxury resale space" cheers Stifel Nicolaus analyst Scott Devitt. He is one of six analysts who have just initiated coverage on REAL. Four analysts started the stock at buy with two staying sidelined. Their $30.20 average price target translates into 20% upside potential.Devitt believes that REAL provides a "superior marketplace experience." Crucially there is a rigorous authentication process to ensure genuine luxury items. As the company stated in its IPO filing: "Trust is the cornerstone of our online marketplace… We believe the trust and personal relationships that we have built with both consignors and buyers over the past eight years cannot be easily replicated."What's more Devitt notes that the secondhand personal luxury goods market is growing over 2x faster than the primary market. In addition, there is an estimated $198 billion in luxury goods potentially available for sale in U.S. homes. "As more individuals become comfortable buying and selling pre-owned goods, there is a strong opportunity to unlock supply supporting long-term growth" states the analyst. * 7 Stocks to Sell This Summer Earnings Season With strong revenue growth of 35% CAGR over the next three years, the analyst expects the company to break even in 2022. Get the REAL Stock Research Report. Netflix (NFLX)Source: Shutterstock Should you buy Netflix (NASDASQ:NFLX) right now? There is no escaping the fact that Netflix disappointed with its Q2 earning results. Shockingly weak Q2 subscriber additions numbers sent shares plunging 16%. However I would argue that now is the time to buy rather than sell. And this is a message backed by the Street, which has a "strong buy" NFLX stock consensus.One analyst sticking by his bullish call is Monness' Brian White. Out of over 5,000 tracked analysts, White is ranked No. 9 for his strong stock picking skills. Plus his NFLX price target is even higher than average at $440 (43% upside potential). The $412 average analyst price target indicates 24% upside potential."We expect this noise will prove to be a fleeting issue and reiterate our BUY rating" cheered White. "Netflix reported a big 2Q:19 paid streaming net additions miss but served up a healthy 3Q:19 outlook."SunTrust Robinson analyst Matthew Thornton calls the 3Q content slate "easily the most robust to date." Notably "Stranger Things" Season 3 had a whopping 40.7 million accounts watching in the first four days, According to a Tweet from Netflix. That's "more than any other film or series in its first four days." Thornton also cites hits like La Casa de Papel (No. 1 Spanish language show), Sacred Games (No. 1 Indian show) and new content from Ryan Murphy and the Obamas. Get the NFLX Stock Research Report. OrganiGram (OGI)OrganiGram Holdings (NASDAQ:OGI) is a top-notch cannabis stock. Canada's OGI is a leading original licensed producer of medical cannabis. The company sells both organic and non-organic strains of cannabis, as well as vaporizers and cannabis oils. And it's trading at just around eight times next year's sales, one of the cheapest valuations compared to immediate peers.Even though OGI's fiscal Q3 earnings report missed expectations, its bull picture is firmly intact. CEO Greg Engel blames a failed cloning experiment for a temporary drop in plant yield. He reassured investors: "Not only have our yields returned to historical levels, but we have seen a meaningful increase in average cannabinoid levels in harvests to date in Q4."Looking ahead, the Canadian market is ready to grow significantly, says Engel. That's with more retail stores opening -- particularly in Ontario and Quebec -- as well as the upcoming legalization and availability of edibles and derivative products.Shares are still up 70% year-to-date, while all analysts covering OGI rate the stock a buy. With an average price target of C$12, these analysts see juicy upside potential of 53%. * 10 Stocks to Buy From This Superstar Fund "Organigram is quickly separating itself from other Canadian LPs," enthuses Paradigm analyst Corey Hammill. "It is a low-cost producer, has an established nationwide distribution network and has invested in preparing for Canada's next wave of legalization." So watch this space. Get the OGI Stock Research Report. Uniqure (QURE)Source: Shutterstock Last but by no means least, we have gene-therapy stock Uniqure NV (NASDAQ:QURE). The company has put on a remarkable sprint recently, nearly doubling in the last six months. That's thanks to its ongoing clinical program in hemophilia B, a blood clotting disorder caused by inherited gene mutation.Earlier this month, uniQure presented nine-month data from the Phase 2b trial of AMT-061 in hemophilia B at the ISTH Congress. Following the event, Cantor Fitzgerald's Elemer Piros hiked his price target from $81 to $94 (37% upside potential)."We remain optimistic that uniQure has the best-in-class hemophilia B gene therapy product and will report positive results from the ongoing Phase 3 HOPE-B study (we have restructured our payment model and increased the PoS [probability of success] to 90% from 75%)" Piros revealed."Although the stock has performed +163% YTD vs. +22% for the XBI, we think new interest could emerge from uniQure's pipeline beyond hemophilia B this year (we are newly including a Huntington's disease model)" the analyst added. Indeed uniQure has guided toward initiating a Phase 1/2 study for Huntington's during 2H19. Putting everything together, he expects uniQure to surpass $1 billion in revenue in 2025. Get the QURE Stock Research Report.TipRanks offers investors the latest insight into eight different sectors by tracking the activity of over 5,000 Wall Street analysts. As of this writing, Harriet Lefton did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Semiconductor Stocks to Buy for Your Inner Geek * 7 Stocks to Buy That Save You Money * 4 Stocks to Sell Now The post 7 Stocks to Buy With Over 20% Upside From Current Levels appeared first on InvestorPlace.

  • A Trio of Small Biotech Companies Garnering Attention
    TheStreet.com

    A Trio of Small Biotech Companies Garnering Attention

    The three either have made recent progress toward advancing products in their pipelines or have caught the eye of analysts.

  • PR Newswire

    Syndax Pharmaceuticals Announces FDA Clearance of IND Application for Targeted Menin Inhibitor SNDX-5613 for Relapsed/Refractory Acute Leukemias

    -- SNDX-5613 is a potent, highly selective, oral inhibitor of the interaction of Menin with the Mixed Lineage Leukemia (MLL) protein -- -- Strong tumor growth inhibition and improved survival observed ...

  • PR Newswire

    Syndax to Present at the JMP Securities Life Sciences Conference

    WALTHAM, Mass. , June 13, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing ...

  • Thomson Reuters StreetEvents

    Edited Transcript of SNDX earnings conference call or presentation 6-May-19 8:30pm GMT

    Q1 2019 Syndax Pharmaceuticals Inc Earnings Call

  • 5 Stellar Stocks For Under $10
    TipRanks

    5 Stellar Stocks For Under $10

    You don’t have to pay three-digit sums to find compelling investing opportunities. It’s time to look outside the box at some cheap stocks top analysts are cheering right now. The best way to find these stocks is to use a screener, that way you can open up your investing horizon to a much wider stock pool.Here we used TipRanks’ Stock Screener to find these 5 cheap stocks. Essentially, we looked for 1) stocks with a ‘Strong Buy’ analyst consensus; 2) serious upside potential (i.e. over 20%). And on top of this each one of these stocks comes in at under $10. Note that the consensus is based on ratings from the last three months, so the outlook is pretty up to date. Plus we include top analyst analysis to show just why analysts believe these stocks are so undervalued right now.Let’s take a closer look: Syndax Pharmaceuticals Inc (SNDX – Research Report) Syndax Pharmaceuticals, Inc is a clinical-stage biopharma developing therapies for the treatment of cancer.The company offers significant rewards- but only for investors prepared to shoulder a hefty dose of risk. Shares could surge if the company’s Phase 3 trial of entinostat in metastatic breast cancer is positive. Indeed, Citigroup’s Joel Beatty says that such a catalyst could take shares all the way from $8 to $23. That suggests massive upside potential of 187%. However, the analyst also warns that should the data disappoint, shares could plunge to just $2 (75% downside potential). Look for the data to come in fall 2019 or spring 2020, says Beatty. In the meantime the analyst keeps a buy rating on shares. Encouragingly, the stock also scores a Strong Buy consensus from the Street. “Entinostat has received Breakthrough Therapy Designation in HR+ HER2- breast cancer patients, and we continue to believe that a positive OS assessment in E2112 could occur this year with a launch in 2021” writes HC Wainwright analyst Edward White. This five-star analyst has a $16 price target on shares (100% upside potential). That's just below the $19 average analyst price target. See what other Top Analysts are saying about SNDX. Turtle Beach Corp (HEAR – Research Report) Turtle Beach Corp is one of the leading gaming headset and audio accessory brand. Disappointing 2Q revenue guidance has weighed on shares recently, but it’s not game over for HEAR just yet.All five analysts covering the stock rate HEAR a ‘Buy.’ That’s with an average analyst price target of $23- indicating 150% upside potential from current levels. The best-rated analyst covering the stock is Oppenheimer’s Andrew Uerkwitz.He maintained his buy rating and $24 price target post-results. In a report on May 9 the analyst explained “With healthy fundamentals in video game market and integration of PC gaming accessories business (ROCCAT) well on track, we remain confident in management's ability to stay competitive and return to revenue growth in 2020.”As for the earnings report, the analyst explains that 2Q revenue guidance is lighter than expected, mostly due to order timing volatility in between quarters. However HEAR did reiterate 2019 revenues of $240-248M. “Over a two year basis, we believe Turtle Beach is outgrowing the competition and keeping its leading market share” he concludes. See what other Top Analysts are saying about HEAR. Pareteum Corp (TEUM – Research Report) Pareteum is a rapidly growing global cloud software communications platform. The company offers everything from voicemail and messaging services to data analytics and service fulfilment. Shares have exploded by 150% year-to-date following first-rate Q1 earnings results, and according to the analyst community plenty of upside lies ahead. This ‘Strong Buy’ stock scores 5 recent buy ratings, alongside an $8 average analyst price target (86% upside potential).Pareteum just hosted its first analyst day on May 28 in NYC. “We view this event as another sign of the further and rapid maturation of the company” cheers five-star Northland Securities analyst Michael Latimore. He has an $8.50 price target on shares. According to Latimore, Pareteum has a unique opportunity to be the cloud-based business and operations support system for agile mobile service providers. “TEUM is a top 2019 stock pick…. TEUM remains inexpensive still at only about 4x FY20 revenue v. comps at 10x” writes the analyst. See what other Top Analysts are saying about TEUM. Plug Power Inc (PLUG – Research Report) Plug Power develops cutting-edge fuel cells and hydrogen technologies that are more efficient than conventional batteries. Like Paretuem, PLUG has experienced a remarkable rally, with shares doubling year-to-date.Shares continued to move higher on May 29 following the announcement of an exciting new deal. Plug Power will now deliver hydrogen fuel cell engines to StreeScooter’s electric delivery vehicles. This ties into StreetScooter’s deal to initially deliver 100 hydrogen fuel cell-powered trucks for on-road use to Deutsche Post DHL starting in 2020. According to Plug Power this will provide increased drive time without the need for long charge hours.“We continue to be bullish on PLUG’s technology leadership position in mobile fuel cell applications and are encouraged by commentary about its expanding opportunity set in material handling and over-the-road applications” writes top-rated Oppenheimer analyst Colin Rusch. Four analysts have published buy ratings on PLUG in the last three months. Their average price target of $3.56 translates into upside potential of 37%. See what other Top Analysts are saying about PLUG. ViewRay, Inc. (VRAY – Research Report) Medical device company ViewRay is on a roll right now. The company just reported strong earnings results, and shares are up 47% year-to-date. Sean Lavin of BTIG praised the company’s current investment strategy, noting strong sales and steady sales progress. Indeed, gross orders came in an impressive $12 million above consensus. “This is especially important as it shows VRAY is winning new customers despite the recent competitive entrance from Elekta. While sales and orders can be difficult to predict on a quarterly basis, we believe this is an early sign that the new CEO’s strategy is working” wrote Lavin. The analyst concluded “since orders are likely most important to investors, we view this as a stellar report.”A similarly bullish perspective comes from Cantor Fitzgerald’s Craig Bijou. The analyst left a recent meeting with management "more bullish on the opportunity ahead” for ViewRay. Despite the rally in shares, he still sees ‘significant upside’ potential thanks to increased revenue and margin expansion.Notably, Bijou argues that management's goal to reduce the time from purchase order to revenue recognition could drive "meaningful upside" to Street numbers in 2020. Overall, five analysts have published buy ratings on VRAY in the last three months with an average price target of $13.40 (50% upside potential). See what other Top Analysts are saying about VRAY. Find your own ‘Strong Buy’ stocksHere we covered top stock picks currently trading for under $10. You can discover more compelling 'Strong Buy' stocks with the Top Analyst Stocks tool. This highlights the most promising stocks based on the latest recommendations from the Street's best-performing analysts. Go to Top Analysts Stocks Tool now.

  • PR Newswire

    Sirnaomics Appoints Allan L. Shaw as Chief Financial Officer

    GAITHERSBURG, Md., May 28, 2019 /PRNewswire/ -- Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today announced the appointment of Allan L. Shaw, CPA, as the company's Chief Financial Officer (CFO). Mr. Shaw is a highly regarded biopharmaceutical executive and board member with more than twenty years of financial and strategic leadership experience. "This is a very exciting time for Sirnaomics having recently completed a $47 million financing, reflecting the company's innovation and tremendous potential. I look forward to working with this dedicated and talented team of industry experts to deliver on our shared goal of developing novel therapeutics that address patient care in areas of high unmet medical need," stated Mr. Shaw.

  • Have Insiders Been Buying Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares This Year?
    Simply Wall St.

    Have Insiders Been Buying Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares This Year?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...

  • PR Newswire

    Syndax to Present at the UBS Global Healthcare Conference

    WALTHAM, Mass. , May 14, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing ...

  • Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates
    Zacks

    Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates

    Syndax (SNDX) delivered earnings and revenue surprises of 5.36% and -0.26%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press

    Syndax: 1Q Earnings Snapshot

    On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 53 cents. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...

  • PR Newswire

    Syndax Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Clinical and Business Update

    - E2112 trial passes fourth interim analysis for OS; trial to continue, with next preplanned analysis expected in 4Q19 - - IND filing for targeted menin inhibitor SNDX-5613 on track for 2Q19 - - Company ...

  • PR Newswire

    Syndax to Announce First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 6, 2019

    WALTHAM, Mass., April 29, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its first quarter 2019 financial results on Monday, May 6, after the close of the U.S. financial markets. In connection with the earnings release, Syndax's management team will host a conference call and live audio webcast at 4:30 p.m. ET on Monday, May 6, to discuss the Company's financial results and provide a general business update.

  • PR Newswire

    Syndax Pharmaceuticals Presents Updated Phase 2 Data from ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) at the American Association for Cancer Research 2019 Annual Meeting

    - 19% objective response rate and 36% clinical benefit rate, with 13-month median duration of response in melanoma patients whose disease progressed on or after anti-PD-1 therapy - - Gene expression analyses ...

  • PR Newswire

    Syndax Announces $26.2 Million Offering of Common Stock and Warrants

    WALTHAM, Mass., March 27, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company") (SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it has entered into an agreement with Biotechnology Value Fund, L.P. ("BVF") and other leading life sciences investors for the purchase of 4,366,666 shares of common stock at a purchase price of $6.00 per share, representing a premium of 30% to the share price as of market close on Tuesday, March 26, as well as warrants to purchase up to 2,183,331 shares of common stock at an exercise price of $12.00 per share, and warrants to purchase up to 2,183,335 shares of common stock at an exercise price of $18.00 per share.

  • Thomson Reuters StreetEvents

    Edited Transcript of SNDX earnings conference call or presentation 7-Mar-19 9:30pm GMT

    Q4 2018 Syndax Pharmaceuticals Inc Earnings Call

  • What Do Analysts Think About Syndax Pharmaceuticals, Inc.’s (NASDAQ:SNDX) Earnings Trend?
    Simply Wall St.

    What Do Analysts Think About Syndax Pharmaceuticals, Inc.’s (NASDAQ:SNDX) Earnings Trend?

    Syndax Pharmaceuticals, Inc.'s (NASDAQ:SNDX) latest earnings update in December 2018 showed company earnings became less negative compared to the previous year's level as a result of recent tailwinds Investors mayRead More...